 | • レポートコード：B-MOR-05197 • 出版社/出版日：Mordor Intelligence / 2018年3月 • レポート形態：英文、PDF、112ページ • 納品方法：Eメール（受注後2営業日） • 産業分類：Healthcare |
| Single User（1名様用） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User（7名様用） | ￥666,000 (USD4,500) | ▷ お問い合わせ |
| Corporate User | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、女性用避妊具の世界市場について調べ、女性用避妊具の世界規模、市場動向、市場環境、避妊薬の種類別分析、デバイス別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。 ・イントロダクション ・エグゼクティブサマリー ・女性用避妊具の世界市場インサイト ・女性用避妊具の世界市場環境 ・女性用避妊具の世界市場動向 ・女性用避妊具の世界市場規模 ・女性用避妊具の世界市場規模：避妊薬の種類別 ・女性用避妊具の世界市場規模：デバイス別 ・女性用避妊具の世界市場：地域別市場規模・分析 ・女性用避妊具の北米市場規模・予測 ・女性用避妊具のアメリカ市場規模・予測 ・女性用避妊具のヨーロッパ市場規模・予測 ・女性用避妊具のアジア市場規模・予測 ・女性用避妊具の日本市場規模・予測 ・女性用避妊具の中国市場規模・予測 ・女性用避妊具のインド市場規模・予測 ・女性用避妊具の韓国市場規模・予測 ・関連企業情報・競争状況 |
The global female contraceptives market is estimated to grow at a CAGR of 8.5% during the forecast period. Need to avoid unwanted pregnancies, especially among the teenage women, is one of the major drivers for this market. Government initiatives, promoting the use of contraceptives to avoid unnecessary births, and health benefits from using contraceptives, have also been important factors, instrumental in market growth.
Need to Prevent Unwanted Abortions
When contraception is affordable, abortion should rarely be necessary. The abortion rate is now at an all-time low in the developed countries- it dropped by more than 40 % over the past 25 years. This is because many anti-abortion groups have grown louder in many European countries, in the recent years. In the United States, the teen pregnancy rate is substantially higher than in other western industrialized nations. According to a report published in 2016, there were 62 million American women in their childbearing years (15–44). About 43 million of them (70%) were at risk of unintended pregnancy, i.e., they were sexually active and do not want to get pregnant; however, they could become pregnant if they fail to use a contraceptive method correctly and consistently. Center for Disease Control and Prevention (CDC) identified the need to curb this growth of unwanted pregnancies, and has taken up initiatives to educate and prevent unwanted abortions and pregnancies- emphasis on the usage of contraceptive pills, is one such initiative. So, the rate of abortion is drastically reducing and the usage of contraceptives such as oral contraceptives usage is increasing. The other factors, like the government and NGO initiatives to promote contraception and the emphasis on family planning, are driving the market.
Side Effects Associated with the Use of Contraceptive Drugs and Devices
Nowadays, a woman has a lot of choices, when compared to the olden days, for wanting to ward off pregnancy. Various methods of contraception include, pills, injection, and vaginal rings comprising of synthetic hormones. Every method is filed with its benefits and side effects. For example, oral contraceptive pills is a well-known method, utilized for avoiding unwanted pregnancy or for family planning. The birth control pill is estimated to be used by around 100 million women, across the world. Like most medications, birth control pills too have side effects. In the same way, a few complications are associated with the use of contraceptive devices like Intrauterine Devices (IUD). There have been cases where a copper IUD was responsible for increased menstrual bleeding and cramps. Spotting between periods has been observed in women using copper IUDs. Such side effects, associated with contraceptive methods, are hindering the growth of the female contraceptive market. The rising prevalence of infertility among women and cultural or religious opposition, are restraining the market growth of the female contraceptives.
The United States has the Highest Market Share
In North America, the United States is dominating the female contraceptives market, due to the maximum percentage of the female population in North America that uses the modern contraceptives techniques. Asia-Pacific is expected to record a substantial growth over the forecast period, due to the increasing awareness among people and several government initiatives.
Key Developments in the Market
• October 2017: Lupin acquired Symbiomix Therapeutics LLC.
• June 2017: Johnson & Johnson acquired Actelion.
Major Players: BAYER HEALTHCARE AG, MAYER LABORATORIES INC., PFIZER INC., MYLAN PHARMACEUTICALS INC., TEVA WOMEN’S HEALTH INC., MERCK & CO., JOHNSON & JOHNSON LTD, LUPIN PHARMACEUTICALS LTD, THE FEMALE HEALTH COMPANY, and FUJI LATEX CO. LTD, amongst others
Reasons to Purchase the Report
• Current and future market outlook for female contraceptives, in the developed and emerging markets
• Analyze various perspectives of the market, with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness the fastest growth, during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3-month analyst support, along with the market estimate sheet (in excel)
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
レポート目次1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Need to Prevent Unwanted Abortions
6.1.2 Government and NGO Initiatives to Promote Contraception
6.1.3 Immediate Health Benefits Other than Birth Control
6.1.4 Emphasis on Family Planning
6.2 Market Restraints
6.2.1 Rising Prevalence of Infertility among Women
6.2.2 Cultural or Religious Opposition
6.2.3 Side Effects Associated with the Use of Contraceptive Drugs and Devices
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 Segmentation -by Contraceptive Drugs
7.1.1 Contraceptive Pills
7.1.1.1 Hormonal Pills
7.1.1.1.1 Combined Oral Contraceptive Pill
7.1.1.1.2 Progestin Only Pill
7.1.1.2 Non-Hormonal Pill
7.1.2 Contraceptive Injections
7.1.3 Topical Contraceptives
7.1.4 Spermicides
7.2 Segmentation -by Contraceptive Devices
7.2.1 Female Condoms
7.2.2 Diaphragms and Caps
7.2.3 Vaginal Rings
7.2.4 Contraceptive Sponges
7.2.5 Sub-dermal Contraceptive Implants
7.2.6 Intra Uterine Contraceptive Devices (IUCDs)
7.2.6.1 Copper IUCDs
7.2.6.2 Hormonal IUCDs
7.2.7 Contraceptive Patches
7.2.8 Others
7.3 Segmentation – by Geography
7.3.1 North America
7.3.1.1 United States
7.3.1.2 Canada
7.3.1.3 Mexico
7.3.2 Europe
7.3.2.1 France
7.3.2.2 Germany
7.3.2.3 United Kingdom
7.3.2.4 Italy
7.3.2.5 Spain
7.3.2.6 Rest of Europe
7.3.3 Asia-Pacific
7.3.3.1 China
7.3.3.2 Japan
7.3.3.3 India
7.3.3.4 Australia
7.3.3.5 New Zealand
7.3.3.6 South Korea
7.3.3.7 Rest of Asia-Pacific
7.3.4 Middle East & Africa
7.3.4.1 GCC
7.3.4.2 South Africa
7.3.4.3 Rest of Middle East & Africa
7.3.5 South America
7.3.5.1 Brazil
7.3.5.2 Argentina
7.3.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers and Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Product Launches
9. Key Players
9.1 Bayer HealthCare AG
9.2 Mayer Laboratories Inc.
9.3 Pfizer Inc.
9.4 Mylan Pharmaceuticals Inc.
9.5 Teva Women’s Health Inc.
9.6 Merck & Co.
9.7 Johnson & Johnson Ltd
9.8 Lupin Pharmaceuticals Ltd
9.9 The Female Health Company
9.10 Fuji Latex Co. Ltd
9.11 Others
10. Future of the Market